266 related articles for article (PubMed ID: 35454830)
1. An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma.
Chan SK; O'Sullivan B; Huang SH; Chau TC; Lam KO; Chan SY; Tong CC; Vardhanabhuti V; Kwong DL; Ng CY; Leung TW; Luk MY; Lee AW; Choi HC; Lee VH
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454830
[TBL] [Abstract][Full Text] [Related]
2. Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.
Chan SK; Lin C; Huang SH; Chau TC; Guo QJ; O'Sullivan B; Lam KO; Chau SC; Chan SY; Tong CC; Vardhanabhuti V; Kwong DLW; So TH; Ng CY; Leung TW; Luk MY; Lee AWM; Choi HCW; Pan JJ; Lee VHF
Oral Oncol; 2022 Mar; 126():105736. PubMed ID: 35121396
[TBL] [Abstract][Full Text] [Related]
3. Anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma.
Lu TZ; Zeng FJ; Hu YJ; Fang M; Zhong FY; Chen BJ; Zhang H; Guo QJ; Pan JJ; Gong XC; Huang SH; Liao ZH; Xia Y; Li JG
Cancer Med; 2023 Dec; 12(24):22091-22102. PubMed ID: 38073447
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma.
Li WZ; Wu HJ; Lv SH; Hu XF; Liang H; Liu GY; Lu N; Bei WX; Lv X; Guo X; Xia WX; Xiang YQ
JAMA Netw Open; 2021 Sep; 4(9):e2124721. PubMed ID: 34554238
[TBL] [Abstract][Full Text] [Related]
5. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.
Lee VH; Kwong DL; Leung TW; Choi CW; O'Sullivan B; Lam KO; Lai V; Khong PL; Chan SK; Ng CY; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; So TH; Luk MY; Lee AW
Int J Cancer; 2019 Apr; 144(7):1713-1722. PubMed ID: 30192385
[TBL] [Abstract][Full Text] [Related]
6. Establishing M1 stage subdivisions by incorporating radiological features and Epstein-Barr virus DNA for metastatic nasopharyngeal carcinoma.
Zheng WH; He XJ; Chen FP; Lin L; Huang XD; Zhou HQ; Kou J; Lv JW; Ma J; Zhou GQ; Sun Y
Ann Transl Med; 2020 Feb; 8(4):83. PubMed ID: 32175376
[TBL] [Abstract][Full Text] [Related]
7. Depicting distant metastatic risk by refined subgroups derived from the 8th edition nasopharyngeal carcinoma TNM.
Guo Q; Lu T; Hui Huang S; O'Sullivan B; Zong J; Xiao Y; Xu W; Chen C; Qiu S; Xu L; Zheng W; Chen Y; Lin S; Pan J
Oral Oncol; 2019 Apr; 91():113-120. PubMed ID: 30926056
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.
Kong FF; Pan GS; Du CR; Ni MS; Zhai RP; He XY; Shen CY; Lu XG; Hu CS; Ying HM
Radiother Oncol; 2023 Aug; 185():109721. PubMed ID: 37244356
[TBL] [Abstract][Full Text] [Related]
9. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.
Hui EP; Li WF; Ma BB; Lam WKJ; Chan KCA; Mo F; Ai QYH; King AD; Wong CH; Guo R; Poon DMC; Tong M; Li L; Lau TKH; Wong KCW; Lam DCM; Lo YMD; Ma J; Chan ATC
Ann Oncol; 2020 Jun; 31(6):769-779. PubMed ID: 32217076
[TBL] [Abstract][Full Text] [Related]
10. Comparison between the seventh and eighth edition of the AJCC/UICC staging system for nasopharyngeal cancer integrated with pretreatment plasma Epstein-Barr virus DNA level in a non-Chinese population: secondary analysis from a prospective randomized trial.
Kitpanit S; Jittapiromsak N; Sriyook A; Prayongrat A; Kannarunimit D; Chakkabat C; Lertbutsayanukul C
Jpn J Clin Oncol; 2019 Dec; 49(12):1100-1113. PubMed ID: 31334768
[TBL] [Abstract][Full Text] [Related]
11. Image-based Multilevel Subdivision of M1 Category in TNM Staging System for Metastatic Nasopharyngeal Carcinoma.
Shen L; Li W; Wang S; Xie G; Zeng Q; Chen C; Shi F; Zhang Y; Wu M; Shu W; Pan C; Xia Y; Wu P
Radiology; 2016 Sep; 280(3):805-14. PubMed ID: 27023116
[TBL] [Abstract][Full Text] [Related]
12. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
13. Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases.
Chen FP; Lin L; Liang JH; Tan SH; Ong EHW; Luo YS; Huang L; Sim AYL; Wang HT; Gao TS; Deng B; Zhou GQ; Kou J; Chua MLK; Sun Y
Ther Adv Med Oncol; 2021; 13():17588359211052417. PubMed ID: 34721672
[TBL] [Abstract][Full Text] [Related]
14. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas.
Huang SH; Xu W; Waldron J; Siu L; Shen X; Tong L; Ringash J; Bayley A; Kim J; Hope A; Cho J; Giuliani M; Hansen A; Irish J; Gilbert R; Gullane P; Perez-Ordonez B; Weinreb I; Liu FF; O'Sullivan B
J Clin Oncol; 2015 Mar; 33(8):836-45. PubMed ID: 25667292
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a new staging system for node-negative gastric cancer based on recursive partitioning analysis: An international multi-institutional study.
Lin JX; Wang ZK; Wang W; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Zheng CH; Li P; Zhou ZW; Huang CM
Cancer Med; 2019 Jun; 8(6):2962-2970. PubMed ID: 31070023
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
Ding C; Dai DY; Luo ZK; Wang GY; Dong Z; Qin GJ; Du XJ; Ma J
Oral Oncol; 2024 Apr; 151():106725. PubMed ID: 38430711
[TBL] [Abstract][Full Text] [Related]
17. Prognostication of Half-Life Clearance of Plasma EBV DNA in Previously Untreated Non-metastatic Nasopharyngeal Carcinoma Treated With Radical Intensity-Modulated Radiation Therapy.
Chan SK; Chan SY; Choi HC; Tong CC; Lam KO; Kwong DL; Vardhanabhuti V; Leung TW; Luk MY; Lee AW; Lee VH
Front Oncol; 2020; 10():1417. PubMed ID: 32974150
[No Abstract] [Full Text] [Related]
18. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.
Li J; Chen S; Peng S; Liu Y; Xing S; He X; Chen H
Int J Biol Sci; 2018; 14(5):549-556. PubMed ID: 29805306
[TBL] [Abstract][Full Text] [Related]
19. Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial.
Tang SQ; Chen L; Li WF; Chan ATC; Huang SH; Chua MLK; O'Sullivan B; Lee AWM; Lee NY; Zhang Y; Chen YP; Xu C; Sun Y; Tang LL; Ma J
Radiother Oncol; 2022 Feb; 167():179-186. PubMed ID: 34971660
[TBL] [Abstract][Full Text] [Related]
20. Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study.
Wu YL; Yang KB; Huang Y; Shi JR; He QS; Chen L; Li WF; Huang XD; Lin L; Chen YP; Mao YP; Tang LL; Ma J
Radiat Oncol; 2022 Aug; 17(1):138. PubMed ID: 35941674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
